MECP2 and nervous system disorder: Although there is no overt connection between epigenetic modifications/factors, DNA methylation readers, and brain metabolism, the clinical symptoms of MeCP2-linked neurological disorders have drawn attention to metabolic defects in glucose and cholesterol metabolism, commonly observed in RTT patients.